Lucid Diagnostics’ Post

The DATA keeps rolling in!! Yet another clinical validation study (the fourth, including three peer-reviewed in prestigious journals and one under review) telling the SAME exact story—#EsoGuard performed on samples collected with #EsoCheck has unprecedented performance at detecting #esophageal precancer including early stage (non-dysplastic BE, NDBE) and short (1-3 cm) segments of disease (SS-NDBE). This study’s Negative Predictive Value (NPV) of ~99% provides providers very high confidence that EsoGuard-negatives patients do not have precancer/cancer and its Postive Predictive Value of ~30% demonstrates EsoGuard’s strong clinical utility as a triage test, increasing the positive yield of endoscopy 3-fold and eliminating the need for expensive and invasive endoscopy in the vast majority of at-risk patients recommended for esophageal precancer screening to prevent #esophagealcancer. #earlydetectionsaveslives #cancerprevention #checkyourfoodtube Lucid Diagnostics Nick Shaheen Victoria T. Lee Suman Verma Shaun O'Neil Brian J. deGuzman, MD

We love to share exciting news about successful research, and here's a great example. Curewiki shares the joy of Professor Cédric Blanpain from the Faculty of Medicine at ULB. His research offers hope for a potentially accessible cancer drug for many patients. “The ultimate joy in research is when one finally sees the light at the end of the tunnel*”. Professor Blanpain rejoices that they can confidently say the drug is here, and the molecule shows promise in preventing tumour resistance to chemotherapy and inhibiting metastasis formation. This discovery represents a significant advancement in cancer treatment. While this breakthrough is a world first, there is still a long road from the laboratory to everyday patients. Clinical studies with more patients, particularly those with endometrial cancer, will be necessary to demonstrate the drug's effectiveness in increasing survival rates. Clinical trials play a pivotal role in advancing medical research and bringing hope to the medical world. We are proud to connect patients and volunteers to clinical trials and give access to tomorrow's medical treatments at Curewiki. *Source: RTBF.BE - "Cancer : un nouveau médicament pour diminuer les métastases et la résistance à la chimiothérapie" Source in English: News-Medical Life Sciences - "New drug targets EMT in cancer, reducing metastasis and resistance to chemotherapy" #Clinicaltrials #Curewiki #MedicalAdvancements #CancerTreatment #ResearchBreakthrough #Medicalresearch

We are excited to present another poster presentation using PredicineEPIC™ in collaboration with The First Affiliated Hospital, Zhenjiang University School of Medicine on Day 1 of ASCO GU!     Diagnosis of prostate cancer and benign prostatic hyperplasia based on urinary cell-free DNA methylation characteristics.      The highlights of this poster presentation include:    • Differentially methylated regions (DMRs) were identified using the urine-based genome-wide DNA methylation assay, PredicineEPIC™, as the potential biomarkers for prostate cancer early detection.  • The AUC, sensitivity, and specificity of the prostate cancer detection between cancer and benign were 0.92, 0.86, and 1.0, respectively.  • This data generated by PredicineEPIC™  highlights the viability of methylation profiling in urinary cell-free DNA for prostate cancer. The non-invasive nature of this approach robustly discriminates PCa from BPH, underscoring the promising potential of methylation-based liquid biopsy for the early detection of PCa.    Come and visit Booth #24 and discover our unique liquid biopsy solutions in support of global clinical trials, CDx development and commercialization. Schedule a meeting with the Predicine team: https://lnkd.in/dTJ9tkAu #ASCOGU24 #precisiononcology #diagnostics #NGS #liquidbiopsy #mrd #ctdna 

🌟 Exciting News Alert! 🌟 We're thrilled to announce the publication of our latest research article in iScience, authored by Meritxell Gironella i Cos, Barbara Pardini, Alessio Naccarati, and their esteemed colleagues. This collaborative effort marks a significant milestone in our journey towards understanding colorectal cancer (CRC) and adenoma (AA) detection. The study delves into the intricate world of small nucleolar RNAs (snoRNAs) and their profiles in CRC and AA, revealing fascinating insights into their differences from normal mucosa. What's more, the research highlights the stability of snoRNA profiles across different populations, underscoring their potential as universal biomarkers. Furthermore, the groundbreaking discovery that snoRNAs can be detected in fecal samples by ddPCR opens up new avenues for non-invasive CRC screening methods. We invite you to delve into the details of our study by accessing the full article here: https://lnkd.in/dd86rb27. Stay tuned for more updates on our research endeavors! #ColoMARK #ResearchCollaboration #CRC #CancerResearch

🌟 We had a blast at the ESMO - European Society for Medical Oncology Asia Congress 2023! 🌟 NalaGenetics proudly engaged at the forefront of oncology innovation during the recent ESMO Asia Congress 2023 – a remarkable platform for the latest strides in cancer research and clinical advancements in the Asia-Pacific region! The conference showcased cutting-edge scientific breakthroughs focusing on prevalent cancer types in the Asia-Pacific area. The sessions were packed with invaluable multidisciplinary education, reflecting the collaboration of esteemed global and Asia-Pacific oncology associations. Our presentation, "What do women want to see in a personalized breast cancer risk report?", unveiled a qualitative study conducted in partnership with SJH Initiatives, led by the renowned surgical oncologist Dr. Samuel J. Haryono, SpB (K) Onk, National University Health System (NUHS), A*STAR - Agency for Science, Technology and Research, and UC Irvine. This presence came right after the launch of MammoReady™, our groundbreaking personalized breast cancer risk genetic test. With such strides, we envision a future where breast cancer management becomes more navigable. Thank you to ESMO Asia Congress 2023 for fostering groundbreaking discussions and innovations. Looking forward to future collaborations and continued strides towards revolutionizing oncology! Visit our website: www.nalagenetics.com ! #NalaGenetics #ESMOAsiaCongress2023 #PersonalizedHealthcare #Oncology

💡 NEW FINDINGS: CCR Researchers reviewed recent data from a trial testing therapy for biochemically recurrent prostate cancer and current PSMA PET imaging options. They suggest that BCR management be individualized and treatment options beyond ADT-based strategies should be explored. ➡ Read more: https://lnkd.in/euShyKQs These findings were largely led by Dr. Ravi A. Madan, a Senior Clinician in our Genitourinary Malignancies Branch. Dr. Madan's clinical research is focused on several aspects of prostate cancer including early recurrent disease, the potential role of immunotherapy in treating the disease, and the emerging utility of PET imaging. These clinical trials span the natural history of prostate cancer from newly diagnosed patients, to early recurrent disease and advanced castration-resistant metastatic prostate cancer. National Cancer Institute (NCI), National Institutes of Health (NIH): Intramural Research Program (IRP) Video credit: iStock #CancerResearch #ProstateCancer #Innovation #Technology

We are attending the #ESMOGI24 congress. 👨⚕️ This congress provides an opportunity to share the latest scientific and medical advances in the field of gastrointestinal cancers. At Servier, we aim to be a focused and innovative player in oncology. Each year, we invest over 70% of our 🔬R&D budget to oncology, particularly to developing treatments for hard-to-treat cancers.  We look forward to seeing you at our booth – N° 2 - and our symposiums: 📌 June 27 - 12:45 - 1:45 pm (CEST) - “Perspectives on the Current and Future Management of mCRC: Consensus and Controversies” 📌 June 27 - 6:15 - 7:15 pm (CEST) - “Providing Cutting-Edge Care for Cholangiocarcinoma: Transforming the Patient Journey” - PeerVoice CME CCA Industry Satellite Symposium supported by Servier, Incyte and Taiho Oncology, Inc. 📌 June 28 - 1:15 - 2:15 pm (CEST) - “Pathways to Enhance Patients’ Benefits in Metastatic Pancreatic Cancer” Learn more about Servier’s commitments 👉 https://swll.to/U8TPQUD #GICancer #GastroIntestinalcancers #oncology #gastroenterology ESMO - European Society for Medical Oncology

We are excited to announce that Galvanize Therapeutics has unveiled promising data from the INCITE-ES clinical study at the recent Society for Immunotherapy for Cancer (#SITC) conference, which evaluated the ability of the Aliya™ #PulsedElectricField (#PEF) system to induce adaptive anti-tumor immunity in patients with Non-Small Cell Lung Cancer (NSCLC). Initial results from the study highlight the potential for the Aliya PEF system to enhance the body's natural defenses against tumors. To view the press release, visit https://prn.to/47DL6WD! For more information related to the #Aliya PEF System, visit https://lnkd.in/gjHWgiJE. #NSCLC #PEF #iPeeps #InterventionalRadiology #InterventionalOncology #iRAD #MedEd #LungCancer #NonSmallCellLungCancer #TwittIR #MedTwitter #SITC23 #SITC2023 #EarlyStageNonSmallCellLungCancer The AliyaTM System is 510(k) cleared in the United States for the surgical ablation of soft tissue. It is not currently commercially available in any other geography. Galvanize Therapeutics® does not promote the off-label use of its products and nothing herein is intended to promote an off-label use of the Aliya System. The Aliya System is a tool for the surgical ablation of soft tissues, and is not intended to treat, cure, prevent or mitigate any specific disease or condition.

🔬 Functional Precision Medicine: Latest Insights  📚Functional precision oncology must beTwo groundbreaking studies shed light on using tumor-derived organoids for precision medicine in colorectal cancer: Ooft et al. (ESMO Open, 2021) conducted a trial on 61 patients, revealing organoid drug sensitivity but no clinical responses. Jensen et al. (J Exp Clin Cancer Res, 2023) studied 90 patients, reporting improved outcomes with individualized treatments based on organoid testing. 🛑Challenges remain, including organoid generation and timely result delivery. 🔮However, upcoming research by Cartry et al. offers promising solutions, paving the way for future clinical trials. 🔗Learn more by reading our latest published article on PDOs in functional precision medicine : Cartry et al. (PMID: 37880806) These findings mark a significant step in advancing personalized cancer care, emphasizing the need for ongoing innovation! #PrecisionMedicine #CancerResearch #OrganoidTechnology #ClinicalTrials

Regulatory science meets oncology ->-> April 16 <-<- The significant rise in marketing authorizations of cancer treatments and the scientific advancements on the horizon, there is a strong need for sharing knowledge and fostering connections among professionals dedicated to cancer therapy innovation, both from industry, academia and regulators. At the Princess Maxima Center for pediatric oncology, Regulatory Science CBG-MEB is hosting its annual Science Day in collaboration with the Oncode Accelerator's Regulatory Innovation Workstream. The program will kick off with Esther Broekman, clinical assessor at the MEB and medical oncologist at UMCG, who will set the scene on the current and future landscape of anticancer medicinal products. Afternoon sessions will delve into: - cutting-edge use of organoids in cancer research, with Jarno Drost offering an academic perspective and Peter Theunissen discussing the regulatory viewpoint.  - the transition from Marketing Authorisation to Clinical Practice, featuring insights from Lourens Bloem, Patrick Kemmeren, Peter Mol, and Gabe Sonke. The Science Day is an opportunity to engage with peers in regulatory science that have a shared aim of innovating the regulatory science space for impact on future therapies. There are poster sessions from PhDs, panel discussions, and ample networking opportunities. Registration is open and attendance is free of charge: https://lnkd.in/evZ8sNpR #MEBScienceDay2024 #OncologyInnovation #RegulatoryScience #CancerResearch